FIELD REVIEW / GLP-1 RECEPTOR AGONIST
Semaglutide: What the STEP, SUSTAIN, SELECT, and PIONEER Trials Actually Measured
Fourteen thousand participants, multiple regulatory decisions, two decades of clinical evidence. A hard-wearing, plainspoken review of the semaglutide research record — strengths named, limitations stated, every quantitative claim cited.
The Semaglutide evidence base: what it covers
Semaglutide is a synthetic GLP-1 receptor agonist studied across more than twenty registered clinical trials spanning type 2 diabetes management, weight reduction in obesity, and cardiovascular risk reduction. The compound carries multiple FDA approvals and one of the largest Phase 3 clinical trial programs for any single peptide-derived compound in recent history.
The core findings are reproducible: once-weekly subcutaneous semaglutide at 2.4 mg produced mean body-weight reduction of 14.9% at 68 weeks versus 2.4% with placebo in STEP 1 (N=1,961) [1]. Two-year data from STEP 5 sustained that effect at 15.2% mean reduction [2]. The SELECT trial (N=17,604) documented a 20% reduction in major adverse cardiovascular events in adults with obesity but without diabetes over 208 weeks [7].
Those are the headline numbers. The gaps matter too: weight regain after discontinuation averages 11.6 percentage points within one year [3]; absolute lean body mass decreases alongside fat mass [15]; GI adverse effects are dose-dependent and present in the majority of trial participants during escalation phases [13]. This site documents both.
For semaglutide dosing protocols, semaglutide side effects, and semaglutide for weight loss, dedicated pages cover the respective literature in depth.
Semaglutide as a GLP-1 Receptor Agonist
Semaglutide shares 94% sequence homology with native GLP-1, modified with two structural changes that extend its half-life from approximately 2 minutes (native GLP-1) to approximately 145-168 hours [10]. The Aib8 substitution confers resistance to dipeptidyl peptidase-4 (DPP-4) cleavage; the C18 fatty diacid chain at Lys26, via a glutamate linker, enables reversible albumin binding that slows renal clearance [12].
The result: once-weekly subcutaneous dosing in clinical studies. Native GLP-1 could not sustain the physiological effect across that interval; semaglutide's structural modifications are specifically engineered to do so.
GLP-1 receptors are expressed in pancreatic beta cells, hypothalamic appetite circuits, the brainstem (area postrema and nucleus tractus solitarius), and the gastrointestinal tract. Semaglutide activates all of these. The multi-site activation is what produces the compound's overlapping glycemic, weight, and cardiovascular effects documented across the STEP, SUSTAIN, and SELECT programs.
What is Semaglutide?
A 31-amino acid synthetic analogue of human GLP-1, molecular weight 4113.6 Da. Available in two formulations studied clinically: once-weekly subcutaneous injection and once-daily oral tablet. The structural modifications are the point — semaglutide is not simply a GLP-1 analogue but a specifically engineered half-life extension of it [12].
FDA approval history: subcutaneous injection for type 2 diabetes (2017), oral tablet for type 2 diabetes (2019), subcutaneous injection for chronic weight management (2021), and a cardiovascular risk reduction label expansion following the SELECT trial results (2024). Compounded formulations produced outside the FDA-approved manufacturing chain are not approved and have been the subject of FDA safety warnings regarding dosing errors and product quality concerns.
Is Semaglutide a GLP-1 receptor agonist?
Yes. Semaglutide is a synthetic analogue of human GLP-1 with 94% sequence homology, modified with a C18 fatty diacid chain and two amino acid substitutions (Aib8, Arg34) that extend half-life from approximately 2 minutes (native GLP-1) to approximately 168 hours [12]. The extended half-life enables once-weekly subcutaneous dosing or once-daily oral dosing in clinical protocols.
Trial record: scope and coverage
The semaglutide clinical program is one of the largest for any GLP-1 receptor agonist. STEP 1-5, STEP TEENS — weight management. SUSTAIN 1-6 — type 2 diabetes glycemic control and cardiovascular safety. PIONEER 1-8 — oral formulation (type 2 diabetes). SELECT — cardiovascular outcomes in obesity without diabetes. Across these programs: tens of thousands of participants, multiple years of follow-up, multiple pre-specified secondary endpoints covering cardiometabolic biomarkers, body composition, and quality of life.
This site covers the published findings from that record — mechanism, efficacy, safety profile, pharmacokinetics, and the open questions the trials have not yet answered. See the semaglutide mechanism of action section on the research page, cardiovascular outcomes research for SELECT and SUSTAIN-6 data, and frequently asked questions for direct answers to the most-searched questions about the compound.